

PD Dr. med. Beyhan Ataseven
Klinik für Gynäkologie und Gynäkologische Onkologie
Evang. Kliniken Essen-Mitte

Hiermit lege ich offen, dass ich von folgenden Firmen finanzielle Unterstützung erhalten habe, die sich auf Vorträge, die Teilnahme an Advisory Boards, allgemeine Beratung und ungebundene Forschungsunterstützung beziehen:

- Roche
- AstraZeneca
- Tesaro
- Amgen
- PharmaMar
- Celgene
- Clovis

Dr. med. Ingo Bauerfeind
Frauenklinik
Klinikum Landshut

2018

Honorare aus Vorträgen oder Advisory Boards

- Celgene
- Aristo
- Roche
- Novartis

2019

keine COIS

(mit Ausnahme der Gipfelstürmerversammlung)

Prof. Dr. med. Michael Braun
Frauenklinik
Rotkreuzklinikum München

Advisory board/ honoraria and travel expenses

- AstraZeneca
- Celgene
- Eisai
- Genomic Health
- GlaxoSmithKline
- medac
- Novartis
- Pfizer
- Roche
- RTI Surgical
- Teva

Dr. med. Johannes Ettl
Klinik und Poliklinik für Frauenheilkunde
Klinikum rechts der Isar der Technischen Universität München

	Firma
Clinical investigator	TRIO, Pfizer, Roche, Celgene, Novartis, Lilly, Medivation, AstraZeneca
Adboard/Berater	Pfizer, Lilly, Novartis, Roche, Tesaro, Eisai, Nektar
Referentenhonorare/Reisekosten u.a.	Roche, Celgene, Pfizer, Amgen, Novartis, Eisai, Roche, Lilly, Novartis, Teva

Prof. Dr. med. habil. Bernd Gerber
Universitätsfrauenklinik und Poliklinik
Klinikum Südstadt Rostock

2017-18

AB / Honorare / Kongresse

Agendia, Amgen, Astra Zeneca, Celgene, Daiichi-Sankyo, Genomic Health, Lilly, MSD, Novartis, Odonate, Pfizer, Roche, Sandoz/Hexal, Seattle Genetics

Aktien

Keine

Forschungsgelder

DFG 140 T€

DKH

4,6 Mill €

Prof. Dr. med. Nadia Harbeck
Brustzentrum
LMU-Frauenklinik Campus Großhadern und Campus Innenstadt, München

Honorare für Beratung und/oder Vorträge

Agendia, Amgen, Astra Zeneca, Celgene, Daiichi-Sankyo, Genomic Health, Lilly, MSD, Novartis, Odonate, Pfizer, Roche, Sandoz/Hexal, Seattle Genetics

Drittmittelgelder für Forschungsprojekte

alle an meine Institution (zahlreiche klinische Phase II-III Studien)

Sonstiges

Co-Director Westdeutsche Studiengruppe (WSG)

Prof. Dr. med. Jens Huober
Frauenklinik
Universitätsklinikum Ulm

Honoraria, consultancy or advisory role

Lilly, Novartis, Roche, Pfizer, Hexal, Astra Zeneca, MSD, Celgene, Eisai

Research funding paid to institution

Novartis, Celgene

Travel expenses

Roche, Pfizer, Novartis, Celgene, Daichi

Prof. Dr. med. Thorsten Kühn
Frauenklinik
Klinikum Esslingen

Vortrags- und Beraterhonorare

- Roche
- Novartis
- Celgene
- Pfizer

Prof. Dr. med. Diana Lüftner
Medizinische Klinik mit Schwerpunkt Hämatologie und Onkologie
Charité – Universitätsmedizin Berlin, Campus Benjamin Franklin

Prof. Dr. med. Diana Lüftner has received honoraria for Advisory Board activities and/or oral presentations from

- Amgen
- AstraZeneca
- Celgene
- Lilly
- Loreal
- MSD
- Mundipharma
- Mylan
- Novartis
- Pfizer
- Roche
- Teva
- Tesaro

Prof. Dr. med. Michael P. Lux
Kliniken für Gynäkologie und Geburtshilfe
Frauenklinik St. Louise, Paderborn

Advisory Boards

Lilly, AstraZeneca, MSD, Novartis, Pfizer, Eisai, Grünenthal, Tesaro, Genomic Health und Roche Pharma

Vorträge

Lilly, Roche, Novartis, Pfizer, Genomic Health, AstraZeneca und Eisai

Reisekosten

Roche und Pfizer

Editorialboard

medac

Prof. Dr. med. Frederik Marmé
Frauenklinik
Universitätsklinikum Heidelberg

Beratungs-, Vortragshonorare, Reisekosten und Forschungsförderung:

- AstraZeneca
- Tesaro
- Roche
- Novartis
- Pfizer
- PharmaMar
- GenomicHealth
- CureVac
- Amgen
- Eisai
- MSD
- Celgene
- Clovis
- Vaccibody

Prof. Dr. med. Achim Rody
Klinik für Frauenheilkunde und Geburtshilfe
Universitätsklinikum Schleswig-Holstein, Campus Lübeck

Honorare

- Roche
- AstraZeneca
- Pfizer
- Celgene
- Eisai
- Novartis
- MSD
- Hexal

ICMJE Form for Disclosure of Potential Conflicts of Interest

Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

1. Identifying information.
2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party – that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

5. Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued

Issued: The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your patent

ICMJE Form for Disclosure of Potential Conflicts of Interest

Section 1. Identifying Information

1. Given Name (First Name) Andreas	2. Surname (Last Name) Schneeweiss	3. Date 20-May-2019
4. Are you the corresponding author?	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No	Corresponding Author's Name _____
5. Manuscript Title _____		
6. Manuscript Identifying Number (if you know it) _____		

Section 2. The Work Under Consideration for Publication

Did you or your institution at any time receive payment or services from a third party (government, commercial, private foundation, etc.) for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc.)?

Are there any relevant conflicts of interest? Yes No

ADD

Section 3. Relevant financial activities outside the submitted work.

Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the "Add +" box. You should report relationships that were present during the 36 months prior to publication.

Are there any relevant conflicts of interest? Yes No

If yes, please fill out the appropriate information below.

Name of Entity	Grant?	Personal Fees?	Non-Financial Support?	Other?	Comments	
Celgene	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Research Grant	X
Roche	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Research Grant	X
AbbVie	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Research Grant	X
Molecular Partner	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Research Grant	X
Roche	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Expert testimony	X
AstraZeneca	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Expert testimony	X
Celgene	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Travel expenses	X
Roche	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Travel expenses	X



SAVE

ICMJE Form for Disclosure of Potential Conflicts of Interest

Name of Entity	Grant?	Personal Fees?	Non-Financial Support?	Other?	Comments	
Roche	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Honoraria	×
Celgene	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Honoraria	×
Pfizer	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Honoraria	×
AstraZeneca	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Honoraria	×
Novartis	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Honoraria	×
MSD	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Honoraria	×
Tesaro	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Honoraria	×
Lilly	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Honoraria	×
Pfizer	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Travel Expenses	×

ADD

Section 4. Intellectual Property -- Patents & Copyrights

Do you have any patents, whether planned, pending or issued, broadly relevant to the work? Yes No

Section 5. Relationships not covered above

Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

- Yes, the following relationships/conditions/circumstances are present (explain below):
 No other relationships/conditions/circumstances that present a potential conflict of interest

At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.



SAVE

ICMJE Form for Disclosure of Potential Conflicts of Interest

Section 6. Disclosure Statement

Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.

Generate Disclosure Statement

Dr. Schneeweiss reports grants from Celgene, grants from Roche, grants from AbbVie, grants from Molecular Partner, personal fees from Roche, personal fees from AstraZeneca, personal fees from Celgene, personal fees from Roche, personal fees from Roche, personal fees from Celgene, personal fees from Pfizer, personal fees from AstraZeneca, personal fees from Novartis, personal fees from MSD, personal fees from Tesaro, personal fees from Lilly, personal fees from Pfizer, outside the submitted work.

Evaluation and Feedback

Please visit <http://www.icmje.org/cgi-bin/feedback> to provide feedback on your experience with completing this form.

PD Dr. med. Marc Thill
 Klinik für Gynäkologie und Gynäkologische Onkologie
 Agaplesion Markus Krankenhaus, Frankfurt/Main

	Applicability	Company
(1) Advisory role		Amgen, AstraZeneca, Biom'Up, Celgene, Daiichi Sankyo, Eisai, Genomic Health, Lilly, MSD, Norgine, Neodynamics, Novartis, Pfizer, pfm Medical, Roche, RTI Surgical, Tesaro
(2) Lecture/speaker engagement fees		Amgen, AstraZeneca, Celgene, Clovis, Eisai, Genomic Health, Hexal, MCI, Medtronic, MSD, Novartis, Omniamed, Pfizer, pfm Medical, Roche, RTI Surgical
(3) Manuscript fees		Amgen, Celgene
(4) Other remuneration	Trial Funding	Genomic Health

Prof. Dr. med. Michael Untch
Frauenklinik
Helios Klinikum Berlin-Buch

Liste Firmen Referenten- und Beraterverträge

- Abbie
- Amgen
- AstraZeneca
- BMS
- Celgene
- Daichi Sankyo
- Eisai
- Janssen Cilag
- Johnson&Johnson
- Lilly
- MSD Merck
- Mundipharma
- Myriad Genetics
- Odonate
- Pfizer
- Puma Biotechnology
- Riemser
- Roche
- Sanofi Aventis
- Sividon Diagnostics
- TEVA

Prof. Dr. med. Wilko Weichert
Institut für Allgemeine Pathologie und Pathologische Anatomie
Technische Universität München

Vortrags- und Beratertätigkeit

- Roche
- MSD
- Bristol-Myers Squibb
- AstraZeneca
- Pfizer
- Merck
- Lilly
- Boehringer
- Novartis
- Takeda
- Amgen

Prof. Dr. med. Achim Wöckel
Frauenklinik und Poliklinik
Universitätsklinikum Würzburg

Honorare für Beratung/ Vorträge/Unterstützung von Fachfortbildungen

- Amgen
- AstraZeneca
- Aurikamed
- Celgene
- Eisai
- Lilly
- MSD
- Novartis
- Pfizer
- Roche
- Tesaro

Dr. med. Rachel Würstlein
Brustzentrum, LMU-Frauenklinik
Campus Großhadern und Campus Innenstadt, München

- Agendia
- Amgen
- AstraZeneca
- Boeringer Ingelheim
- Carl Zeiss
- Celgene
- Daiichi Sankyō
- Eisai
- Genomic Health
- Glaxo Smith Kline
- Hexal
- Lilly
- MSD
- Mundipharma
- Nanostring
- Novartis
- Odonate
- Paxman
- Palleos
- Pfizer
- Pierre Fabre
- Puma Biotechnology
- Riemser
- Roche
- Sandoz/Hexal
- Seattle Genetics
- Tesaro Bio
- Teva